Real world evidence

Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit Hyperactivity Disorder in Denmark and Sweden - A Population-Based Cohort Study

To our knowledge, this is the first population-based observational study using routinely collected administrative data from clinical practice to investigate the cardiovascular and cerebrovascular risk associated with exposure to LDX. Results of the current study suggest that there is little to no increased risk of cardiovascular and cerebrovascular events among patients treated with LDX compared with patients previously treated with other ADHD medications.